Maven Securities’s Gain Therapeutics GANX Stock Holding History

Maven Securities’s Portfolio GANX Stock Details GANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-22,124	Closed	-$340K	–	1153
2021 Q1	$340K	Buy	+22,124	New	+$290K	0.02%	776

Other funds holding GANX

Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return

GPCM

Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return

PCM

Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BCV

Banque Cantonale Vaudoise Lausanne, Switzerland $2.66B AUM 26.89% 1-Year Est. Return

Maven Securities's GANX Position: Q2 2021 in Review

Maven Securities sold out of Gain Therapeutics (GANX) in Q2 2021, closing a stake of 22,124 shares — an estimated $340K sold.

Maven Securities first reported a position in GANX in Q1 2021 and held it in 1 quarter. The position peaked at $340K in Q1 2021. 14 funds tracked by Wall St. Rank hold GANX as of Q2 2021.

Maven Securities reported no remaining Gain Therapeutics position as of Q2 2021 after selling out during the quarter.
Maven Securities sold 22,124 Gain Therapeutics shares in Q2 2021, an estimated $340K.
Maven Securities first reported a position in Gain Therapeutics in Q1 2021 and held it in 1 quarter.
Maven Securities's Gain Therapeutics position peaked at $340K in Q1 2021.
14 funds tracked by Wall St. Rank held Gain Therapeutics as of Q2 2021.

Based on Maven Securities's 13F filing for Q2 2021, filed 16 Aug 2021.